Product news from the 08/01/06 News Brief

Share this article:
Product news Takeda Pharmaceuticals North America said the FDA has approved its New Drug Application for Duetact (pioglitazone HCl and glimepiride), for the treatment of type 2 diabetes. Duetact combines the diabetes medications Actos (pioglitazone HCl) and glimepiride in a single tablet. The FDA has approved the expanded indication of Abbott’s rheumatoid arthritis treatment Humira (adalimumab) for reducing signs and symptoms in patients with active ankylosing spondylitis (AS), an autoimmune disease affecting the spine and large peripheral joints that causes inflammatory back pain and stiffness and also can be associated with other inflammatory diseases of the skin, eyes and intestines.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.